Reversal of tacrolimus‐related hypertrophic cardiomyopathy after conversion to rapamycin in a pediatric liver transplant recipient

Abstract:  Tacrolimus (Tac)‐related hypertrophic cardiomyopathy (HCM) has been reported to be an unusual but serious complication affecting pediatric patients after solid organ transplantation. Herein, we present a case of young liver transplant recipient with Tac‐induced HCM, treated by discontinuation of Tac followed by conversion to rapamycin (Rap). Our case report points out the potential but rather low risk of HCM during Tac immunosuppression in pediatric liver transplants and demonstrates that replacement of calcineurin inhibitors with mammalian target of Rap (mTOR) inhibitors may be an efficacious therapeutic tool to effect regression of established cardiac hypertrophy.

[1]  C. Tchervenkov.  Surgical management of transposition in the setting of obstruction within the aortic arch , 2005, Cardiology in the Young.

[2]  E. Benedetti,et al.  Reversal of tacrolimus‐related hypertrophic obstructive cardiomyopathy 5 years after kidney transplant in a 6‐year‐old recipient , 2005, Pediatric transplantation.

[3]  M. Dedmon.  Liver transplantation Managing complications in primary care , 2005, JAAPA : official journal of the American Academy of Physician Assistants.

[4]  D. Glass,et al.  Molecular mechanisms modulating muscle mass. , 2003, Trends in molecular medicine.

[5]  S. Radio,et al.  Asymmetric cardiac hypertrophy at autopsy in patients who received FK506 (tacrolimus) or cyclosporine A after liver transplant1. , 2002, Transplantation.

[6]  B. Varan,et al.  Cardiac evaluation of pediatric liver transplantation candidates. , 2002, Transplantation Proceedings.

[7]  P. Hayes,et al.  Cardiac function after orthotopic liver transplantation and the effects of immunosuppression: A prospective randomized trial comparing cyclosporin (Neoral) and tacrolimus , 2002, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[8]  C. Watson.  Sirolimus (rapamycin) in clinical transplantation , 2001 .

[9]  G. Mazariegos,et al.  Sirolimus for rescue and primary immunosuppression in transplanted children receiving tacrolimus. , 2001, Transplantation.

[10]  R. Branch,et al.  Lack of Tacrolimus-Induced Cardiomyopathy , 2001, The Annals of pharmacotherapy.

[11]  S. McDiarmid,et al.  Echocardiographic findings of hypertrophic cardiomyopathy in children after orthotopic liver transplantation , 2001, Pediatric transplantation.

[12]  W. Robberecht,et al.  Abnormal intracellular ca(2+)homeostasis and disease. , 2000, Cell calcium.

[13]  C. Wippermann,et al.  Normal values of M mode echocardiographic measurements of more than 2000 healthy infants and children in central Europe , 2000, Heart.

[14]  S. Uemoto,et al.  Tacrolimus and myocardial hypertrophy. , 2000, Transplantation.

[15]  A. Tzakis,et al.  Sirolimus in pediatric gastrointestinal transplantation: The use of sirolimus for pediatric transplant patients with tacrolimus‐related cardiomyopathy , 2000, Pediatric transplantation.

[16]  G. Crabtree.  Generic Signals and Specific Outcomes Signaling through Ca2+, Calcineurin, and NF-AT , 1999, Cell.

[17]  S. McDiarmid,et al.  Marked left ventricular hypertrophy in children on tacrolimus (FK506) after orthotopic liver transplantation. , 1998, The American journal of cardiology.

[18]  D. Grant,et al.  Arteritis and increased intracellular calcium as a possible mechanism for tacrolimus-related cardiac toxicity in a pediatric transplant recipient. , 1997, Transplantation.

[19]  E. Seidman,et al.  Hypertrophic cardiomyopathy associated with tacrolimus in paediatric transplant patients , 1995, The Lancet.

[20]  M. Özel,et al.  Small virus-like structure in fractions from scrapie hamster brain , 1994, The Lancet.

[21]  A Nava,et al.  Comparison of QT dispersion in hypertrophic cardiomyopathy between patients with and without ventricular arrhythmias and sudden death. , 1993, The American journal of cardiology.

[22]  M. Vogel,et al.  Comparison of magnetic resonance imaging with cross-sectional echocardiography in the assessment of left ventricular mass in children without heart disease and in aortic isthmic coarctation. , 1992, The American journal of cardiology.

[23]  F. J. Fricker,et al.  Echocardiographic findings before and after liver transplantation. , 1985, The American journal of cardiology.

[24]  T. Fishbein,et al.  Treatment of tacrolimus-related adverse effects by conversion to cyclosporine in liver transplant recipients , 2000, Transplant international : official journal of the European Society for Organ Transplantation.

[25]  Linda Sher,et al.  A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. , 1994, The New England journal of medicine.